These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 1806162)

  • 1. Adverse drug reactions: an integrated approach.
    Ti TY; MacLeod SM
    Bratisl Lek Listy; 1991 Nov; 92(11):531-3. PubMed ID: 1806162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse drug reactions (ADRs) in children: Part 1.
    Kanneh AB
    Paediatr Nurs; 2004; 16(6):32-5. PubMed ID: 15328727
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacoepidemiological characterization of drug-induced adverse reaction clusters towards understanding of their mechanisms.
    Mizutani S; Noro Y; Kotera M; Goto S
    Comput Biol Chem; 2014 Jun; 50():50-9. PubMed ID: 24534381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Drug safety: from development to clinical use].
    Ovchinnikova EA; Gerasimov VB
    Antibiot Khimioter; 2006; 51(6):15-22. PubMed ID: 17523417
    [No Abstract]   [Full Text] [Related]  

  • 5. Drug safety in relation to efficacy: the view of a clinical pharmacologist.
    Sjöqvist F
    Pharmacol Toxicol; 2000; 86 Suppl 1():30-2. PubMed ID: 10905752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety pharmacology--a progressive approach.
    Redfern WS; Wakefield ID; Prior H; Pollard CE; Hammond TG; Valentin JP
    Fundam Clin Pharmacol; 2002 Jun; 16(3):161-73. PubMed ID: 12165064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of adverse drug reactions using hospital databases-a nationwide study in Portugal.
    Miguel A; Bernardo Marques ; Freitas A; Lopes F; Azevedo L; Pereira AC
    Pharmacoepidemiol Drug Saf; 2013 Aug; 22(8):907-13. PubMed ID: 23761351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can pharmacogenetics help rescue drugs withdrawn from the market?
    Shah RR
    Pharmacogenomics; 2006 Sep; 7(6):889-908. PubMed ID: 16981848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are non-serious adverse reactions to psychiatric drugs really non-serious?
    Pozzi M; Bertella S; Cattaneo D; Molteni M; Perrone V; Carnovale C; Antoniazzi S; Clementi E; Radice S
    J Child Adolesc Psychopharmacol; 2013 Aug; 23(6):394-400. PubMed ID: 23952186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Understanding and reducing the risk of adverse drug reactions in pediatric patients].
    Gotta V; van den Anker J; Pfister M
    Ther Umsch; 2015 Dec; 72(11-12):679-86. PubMed ID: 26654811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Dealing with adverse drug reactions in dentistry. Procedures on encountering adverse drug reactions and goal of the Swiss Pharmacovigilance system].
    Egger SS; Krähenbühl S; Schlienger RG
    Schweiz Monatsschr Zahnmed; 2005; 115(12):1209-18. PubMed ID: 16408825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pattern of adverse drug reactions notified by spontaneous reporting in an Indian tertiary care teaching hospital.
    Jose J; Rao PG
    Pharmacol Res; 2006 Sep; 54(3):226-33. PubMed ID: 16781163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spontaneous reporting of adverse drug reactions in elderly patients in Sicily (Italy).
    Cutroneo P; Greco S; Cucinotta G; Arcoraci V; Caputi AP
    Pharmacol Res; 1999 Jul; 40(1):41-6. PubMed ID: 10378989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EUDRAGENE: European collaboration to establish a case-control DNA collection for studying the genetic basis of adverse drug reactions.
    Molokhia M; McKeigue P
    Pharmacogenomics; 2006 Jun; 7(4):633-8. PubMed ID: 16753010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Refill adherence and self-reported adverse drug reactions and sub-therapeutic effects: a population-based study.
    Hedna K; Hägg S; Andersson Sundell K; Petzold M; Hakkarainen KM
    Pharmacoepidemiol Drug Saf; 2013 Dec; 22(12):1317-25. PubMed ID: 24127242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Management of adverse drug effects].
    Schlienger RG
    Ther Umsch; 2000 Sep; 57(9):584-90. PubMed ID: 11036440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenomic profiling in postmarketing surveillance: prospects and challenges.
    Issa AM
    Pharmacogenomics; 2003 Sep; 4(5):647-55. PubMed ID: 12943471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A survey of spontaneous reporting of adverse drug reactions in 10 years of activity in a pharmacovigilance centre in Portugal.
    Marques J; Ribeiro-Vaz I; Pereira AC; Polónia J
    Int J Pharm Pract; 2014 Aug; 22(4):275-82. PubMed ID: 24188533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Canadian Pharmacogenomics Network for Drug Safety: a model for safety pharmacology.
    Ross CJ; Visscher H; Sistonen J; Brunham LR; Pussegoda K; Loo TT; Rieder MJ; Koren G; Carleton BC; Hayden MR;
    Thyroid; 2010 Jul; 20(7):681-7. PubMed ID: 20578893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outlier removal to uncover patterns in adverse drug reaction surveillance - a simple unmasking strategy.
    Juhlin K; Ye X; Star K; Norén GN
    Pharmacoepidemiol Drug Saf; 2013 Oct; 22(10):1119-29. PubMed ID: 23832706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.